Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.42 Friday, 10th May 2024 CANF stock ended at $2.09. This is 2.42% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 3.29% from a day low at $2.05 to a day high of $2.12.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Oct 20, 2016 $2.43 $2.44 $2.36 $2.42 15 800
Oct 19, 2016 $2.45 $2.45 $2.34 $2.41 84 600
Oct 18, 2016 $2.42 $2.48 $2.40 $2.45 18 600
Oct 17, 2016 $2.45 $2.49 $2.36 $2.40 19 000
Oct 14, 2016 $2.52 $2.53 $2.36 $2.44 39 400
Oct 13, 2016 $2.45 $2.56 $2.44 $2.51 16 800
Oct 12, 2016 $2.50 $2.56 $2.42 $2.48 23 100
Oct 11, 2016 $2.59 $2.59 $2.42 $2.47 50 600
Oct 10, 2016 $2.50 $2.63 $2.47 $2.58 76 800
Oct 07, 2016 $2.56 $2.59 $2.40 $2.50 55 700
Oct 06, 2016 $2.68 $2.68 $2.55 $2.59 63 500
Oct 05, 2016 $2.61 $2.69 $2.58 $2.68 40 800
Oct 04, 2016 $2.66 $2.71 $2.57 $2.62 59 800
Oct 03, 2016 $2.66 $2.68 $2.56 $2.59 24 500
Sep 30, 2016 $2.60 $2.74 $2.57 $2.62 41 700
Sep 29, 2016 $2.77 $2.79 $2.52 $2.56 124 500
Sep 28, 2016 $2.63 $2.78 $2.63 $2.72 91 800
Sep 27, 2016 $2.66 $2.75 $2.62 $2.69 75 900
Sep 26, 2016 $2.69 $2.69 $2.55 $2.60 55 400
Sep 23, 2016 $2.63 $2.71 $2.55 $2.63 77 500
Sep 22, 2016 $2.62 $2.78 $2.50 $2.68 182 100
Sep 21, 2016 $2.60 $2.64 $2.50 $2.62 100 300
Sep 20, 2016 $2.82 $2.82 $2.48 $2.52 1 107 400
Sep 19, 2016 $2.31 $2.40 $2.24 $2.38 40 700
Sep 16, 2016 $2.31 $2.38 $2.25 $2.31 62 200
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT